Published 1 day ago • loading... • Updated 7 hours ago

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group Plc Securities Fraud Lawsuit

Rosen Law Firm reminds purchasers of Mereo BioPharma Group American Depositary Shares of the April 6, 2026, lead plaintiff deadline for the class action covering securities purchased between June 5, 2023, and December 26, 2025.
The lawsuit alleges Defendants provided misleading statements regarding the true state of the Phase 3 ORBIT and COSMIC programs for Osteogenesis Imperfecta, which failed to hit primary clinical endpoints compared to control groups.
Defendants' "Statements included, among other things, confidence in setrusumab," yet the lawsuit claims neither the ORBIT nor COSMIC studies achieved their primary endpoints of reducing annualized fracture rates versus placebo or control groups.
Investors who purchased Mereo securities during the Class Period may be entitled to compensation without out-of-pocket fees through the pending class action lawsuit seeking to recover damages from alleged securities law violations.
To serve as lead plaintiff, investors must move the Court by April 6, 2026, though participation in potential recoveries does not require serving as lead representative.

Insights by Ground AI

34 Articles

The Courier-Tribune

+30 Reposted by 30 other sources

Center

MREO Deadline: MREO Investors with Losses in Excess of $100K Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit

NEW YORK, March 31, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADS") of Mereo BioPharma Group plc (NASDAQ: MREO) between June 5, 2023 and December 26, 2025 (the "Class…

23 hours ago

Read Full Article